v3.25.4
Discontinued Operations - Schedule of Statement of Operations (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]      
Net loss from discontinued operations $ 0 $ 0 $ (74,429)
Net loss attributable to Bioventus Inc.—discontinued operations     (59,492)
Deconsolidation     60,639
Non-refundable payments     10,150
Discontinued Operations, Disposed of by Sale      
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]      
Cash on hand $ 1,356    
Discontinued Operations, Disposed of by Sale | Carti Heal      
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]      
Selling, general and administrative expense     1,728
Research and development expense     396
Change in fair value of contingent consideration     1,710
Depreciation and amortization     4,264
Operating loss from discontinued operations     (8,098)
Interest expense, net     4,889
Other expense     61,442
Other expense     66,331
Loss attributable to noncontrolling interest—discontinued operations     $ 14,937